C
Comera Life Sciences
Biotech & Life Sciences · Woburn, United States · Founded 2014
Enhancing therapeutic protein formulations for better patient experience and extended product lifecycle MoreLess
Comera Life Sciences operates in the life sciences sector, focusing on transforming intravenous (IV) biologics into subcutaneous (SQ) self-administered injections. This innovation aims to provide patients with the freedom to administer their own medication, reducing the need for time-consuming and costly visits to infusion centers. The company serves patients with significant diseases who rely on biologic therapeutics, offering them a more convenient and less painful treatment option. Comera's business model revolves around developing and commercializing these self-injectable biologics, generating revenue through product sales and potential partnerships with pharmaceutical companies. By leveraging their proprietary platform, Comera aims to maximize the therapeutic potential of biologics, ultimately improving patient outcomes and quality of life.
Keywords: biologics, self-injection, patient care, life sciences, innovation, therapeutics, convenience, healthcare, medical technology, infusion alternatives.
Talent graph
Comera Life Sciences's talent
Source: Dealroom Talent Intelligence.
Investors
4 investors on Comera Life Sciences's cap table
Sourced from Dealroom's funding and investor records.



Global footprint
Where Comera Life Sciences has talent and traffic
Market sentiment
What the market is saying about Comera Life Sciences
An AI-synthesized read of the highest-engagement posts about Comera Life Sciences on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Comera Life Sciences on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.